About Sirna: Sirna Therapeutics: "The scientific community considers RNA RNA
Ribonucleic acid. A long chain polymer of genetic material similar to DNA except that it is usually found in a single-stranded form rather than as a double helix, it is made up of the ribo nucleotides A, G, C, and U (instead of T), it is somewhat less resistant to cellular degradation enzymes than DNA, and it functions most often as a transient messenger of genetic information rather than as a permanent store-house as is the case for DNA.interference (RNAi)RNAi

RNA interference. A natural cellular mechanism by which RNA is recognized as “foreign” due to its existence in a double-stranded form. This results in the degradation of the double-stranded RNA, along with single-stranded RNA having the same sequence. the breakthrough biological discovery of the decade with the potential to change how diseases are treated. Sirna Therapeutics, Inc. is leading the industry in developing a new class of drugs based on RNAi—drugs that we believe will significantly improve human health.
With our unmatched chemistry and biology expertise, seasoned leadership and broad therapeutic pipeline, Sirna is demonstrating that short interfering RNA (siRNA)siRNA
short interfering RNA. An intermediate in the RNAi process in which the long double-stranded RNA has been cut up into short (~21 nucleotides) double-stranded RNA. The siRNA stimulates the cellular machinery to cut up other single-stranded RNA having the same sequence as the siRNA. can be chemically optimized and efficiently delivered to create therapeutically relevant compounds with drug-like properties and clinical effect.

In short, Sirna Therapeutics is at the forefront of the effort to create RNAi-based therapies, leverage the vast potential of this technology to ultimately treat patients in need."